Hormone Receptor Signaling and Therapeutic Targeting

• 2279 · PDF DNA methylation-based classifier predicts SERD benefit in ESR1 wild-type HR+/HER2- breast cancer Shile Zhang, Nicole Zhang, Vishnu Ramani, Tingting Jiang, Marisa Juntilla, Amar Das, Martina Lefterova, Justin Odegaard, Darya Chudova, Matthew Ellis
• 2280 · PDF Ligand-activated AR promotes the survival of endocrine therapy-responsive ER+ breast cancer Patrick Aouad, Eliah Shamir, Jackson Liang, Liang-Fu Chen, Vasumathi Kameswaran, Lisa Crocker, Marc Hafner, Bence Daniel, Antonina Hafner, Ciara Metcalfe
• 2281 2281 AZD4241, an orally bioavailable ERalpha PROTAC, degrades wild-type and mutant ERalpha and delivers anti-tumour activity in preclinical breast cancer models Mandy Lawson, Natalie Cureton, Lynet Nyoni, Sophie D’Arcy, Lydia Parkinson, Ana Quiroga, Pablo Morentin Gutierrez, Ji Li, Hana Baakza, Thomas Hayhow, Claire Crafter, Lucy Ireland, Gemma Hardman Fowler, Georgia M. Simmons, Lakjaya Buluwela, Simak Ali, Neil Gibson
• 2282 · PDF Targeting estrogen receptor mutations and aberrant myelopoiesis in hormone resistant breast cancer Maria Belen Villegas, Mario Morales Martinez, Javier Mansilla, Eduardo Mauricio Gonzalez, Begoña Comin-Anduix, Marisol Chavez, Brian Aguirre, Gang Deng, Nalo M. Hamilton, Madhuri Wadehra, Michael E. Jung, Richard J. Pietras, Diana C. Marquez Garban
• 2283 · PDF Obesity predicts greater changes in Ki67 after neoadjuvant aromatase inhibitor therapy in early-stage ER+ breast cancer Mary Dickinson Chamberlin, Lillian A. Lawrence, Roberta M. DiFlorio-Alexander, Victoria Jones, Eugene Demidenko, Jonathan Marotti
• 2284 2284 Progesterone receptor modulates the antigen processing and presentation machinery: Decreasing MHC class I expression on tumor Julio Tinoco, Eilidh Chowanec, Amanda Glen Heard, Christy R. Hagan
• 2285 · PDF TGFbeta Induction: An essential tumor suppressive arm of next generation SERDs in ER+ breast cancer models in vitro Kareem Heslop, Jackson Liang, Steffan Vartanian, Jinchu Vijay, Liang-Fu Chen, Marc Hafner, Michael Costa, Ciara Metcalfe
• 2286 2286 Monitoring response to camizestrant next-generation oral SERD in ER+ advanced breast cancer patient-derived xenografts via circulating tumor DNA profiling Susana Ros*, Paul Labrousse*, Hugh Russell, Fryer Henderson, Sara Talbot, Benjamin Phillips, Teresa Klinowska, Christopher Morrow, Claire Crafter, Daniel Stetson, Darren Hodgson, James Hadfield
• 2287 · PDF Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming in prostate cancer Songqi Zhang, Muqing Li, Mingyu Liu, Nolan D. Patten, Maryam Labaf, Jaeweon Jeong, HyeonYeong Sun, Jared G. Lourie, Kai Zou, Susan Patalano, Jill A. Macoska, Shuai Gao, Dong Han, Maria Pennuto, Steven P. Balk, Changmeng Cai
• 2288 · PDF Neoadjuvant treatment of ER-positive/HER2-negative breast cancer with aromatase inhibitors in sequence: Ki67 dynamics and biology shifts Kamilla Fjermeros, Julius Johannes Grindahl Hettich, Stephanie Beate Geisler, Unn-Cathrin Buvarp, Hilde Presterud Ødegård, Elin Edda Seland Agustsdottir, Laurens Cornelus Reitsma, Nazli Bahrami, Vessela N. Kristensen, Xavier Tekpli, Torben Lüders, Andliena Tahiri, Manouchehr Seyedzadeh, Torill Sauer, Silje Mathiassen, Sofie Flovik Ranestad, Clara Hammarstrøm, Jürgen Geisler
• 2289 2289 Newly-designed selective estrogen receptor downregulators and their role in the tumor microenvironment and hematopoiesis in breast malignancies Mario Morales Martinez, Javier Mansilla, Eduardo Mauricio Gonzalez, Begoña Comin-Anduix, Marisol Chavez, Brian Aguirre, Julia Aguade Gorgorio, Gang Deng, Nalo M. Hamilton, Hannah Mikkola, Madhuri Wadehra, Michael E. Jung, Richard J. Pietras, Diana C. Marquez Garban
• 2290 2290 Therapeutic targeting of ATAD2 in endocrine-resistant breast cancer Anil Kumar Devakrishnan, Murugesan Palaniappan
• 2291 · PDF Exposure to plastic additives suggests potential androgen receptor agonism in prostate cancer Wylie K. Watlington, Sophia Colmenares, James Carter, Sophie Vincoff, Andrew A. Armstrong, Daniel Reker, Jason A. Somarelli
• 2292 · PDF Interleukin-6 increases glucocorticoid inactivation in a castration resistant prostate cancer cell line model Olivia M. Tonini, Lina Schiffer, Nima Sharifi
• 2293 · PDF The LncRNA XIST mediates resistance to estrogen receptor beta targeted therapies in triple negative breast cancer Michael Emch, Kirsten Aspros, Matthew P. Goetz, John Hawse
• 2294 · PDF Examining the effect of second-generation antiandrogens in androgen receptor-overexpressing prostate cancer cells Kia Vaalavirta, Hanna Rauhala, Tapio Visakorpi
• 2295 · PDF KMT2D loss rewires estrogen-PI3K crosstalk in endometrioid adenocarcinoma Jessica L. Long, Swornalata Pukhrambam, Areebah Qazi, Michele L. Cote, Greg Dyson, Anna Gottschlich, Mike R. Wilson
• 2296 2296 Anti-tumor actions of novel tamoxifen-melatonin drug conjugates on estrogen-resistant tumors and actions on tumor-and uterine-expressed ESR1 in SCID_BEIGE mice Asef Faruk, Sophie Dietrich, Yong Myoung, Afsana Jahan, Mohamed Marzouk, Jane E. Cavanaugh, Simak Ali, Matthew Burow, Darius Zlotos, Paula Witt-Enderby
• 2297 2297 Effects of AVA-291 (d3-testosterone) versus testosterone on MCF-7 estrogen receptor positive breast cancer cells - lack of aromatization to estradiol leads to a highly differentiated cellular proliferation profile Paul M. Tarantino, Judith A. Boice, Pamela A. Trail, Bradford C. Sippy
• 2298 · PDF Spatial immune profiling reveals varying tumor microenvironments in papillary thyroid microcarcinoma Rhitajit Sarkar, Shilpa Thakur, Gus Fridell, Elijah Edmondson, Sonam Kumari, Joanna KLUBO-GWIEZDZINSKA
• LB112 LB112 An orally bioavailable AR-NTD degrader that bypasses LBD-dependent resistance and prevents AR-V7-mediated feedback in advanced prostate cancer Ling-Yu Wang, Chiu-Lien Hung, Wen-Ning Hsu, Tsan-Chun Wang

在会议检索中浏览本分会场